Annexon, Inc. Files 8-K Report
Ticker: ANNX · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1528115
Sentiment: neutral
Topics: disclosure, financials, regulation-fd
Related Tickers: ANNX
TL;DR
ANNX filed an 8-K on 6/4/24 with Reg FD disclosures and financials.
AI Summary
On June 4, 2024, Annexon, Inc. filed an 8-K report detailing a Regulation FD Disclosure and other events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Brisbane, California.
Why It Matters
This 8-K filing provides important updates and disclosures from Annexon, Inc. to the public, including financial information and other material events.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediate negative or positive material events.
Key Numbers
- 001-39402 — SEC File Number (Identifies the specific SEC filing for Annexon, Inc.)
- 27-5414423 — IRS Employer Identification No. (Tax identification number for Annexon, Inc.)
Key Players & Entities
- Annexon, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Brisbane, California (location) — Address of principal executive offices
- (650) 822-5500 (phone_number) — Registrant's telephone number
FAQ
What specific Regulation FD disclosures were made by Annexon, Inc. in this 8-K filing?
The filing indicates a Regulation FD Disclosure was made, but the specific details of the disclosure are not provided in the excerpt.
What are the key items included in the 'Other Events' section of this 8-K?
The excerpt states 'Other Events' is an item information category, but does not specify the content of those events.
Where are Annexon, Inc.'s principal executive offices located?
Annexon, Inc.'s principal executive offices are located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005.
What is the SIC code for Annexon, Inc.?
The Standard Industrial Classification (SIC) code for Annexon, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on June 4, 2024.
Filing Stats: 1,166 words · 5 min read · ~4 pages · Grade level 10.3 · Accepted 2024-06-04 07:05:38
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ANNX The Nasdaq Stock Mar
Filing Documents
- d838099d8k.htm (8-K) — 31KB
- d838099dex991.htm (EX-99.1) — 21KB
- d838099dex992.htm (EX-99.2) — 39KB
- g838099ex99_2p10g1.jpg (GRAPHIC) — 225KB
- g838099ex99_2p11g1.jpg (GRAPHIC) — 196KB
- g838099ex99_2p12g1.jpg (GRAPHIC) — 254KB
- g838099ex99_2p13g1.jpg (GRAPHIC) — 234KB
- g838099ex99_2p14g1.jpg (GRAPHIC) — 252KB
- g838099ex99_2p15g1.jpg (GRAPHIC) — 240KB
- g838099ex99_2p16g1.jpg (GRAPHIC) — 302KB
- g838099ex99_2p17g1.jpg (GRAPHIC) — 308KB
- g838099ex99_2p18g1.jpg (GRAPHIC) — 432KB
- g838099ex99_2p19g1.jpg (GRAPHIC) — 292KB
- g838099ex99_2p1g1.jpg (GRAPHIC) — 406KB
- g838099ex99_2p20g1.jpg (GRAPHIC) — 339KB
- g838099ex99_2p21g1.jpg (GRAPHIC) — 344KB
- g838099ex99_2p22g1.jpg (GRAPHIC) — 272KB
- g838099ex99_2p23g1.jpg (GRAPHIC) — 335KB
- g838099ex99_2p24g1.jpg (GRAPHIC) — 435KB
- g838099ex99_2p25g1.jpg (GRAPHIC) — 364KB
- g838099ex99_2p26g1.jpg (GRAPHIC) — 382KB
- g838099ex99_2p27g1.jpg (GRAPHIC) — 392KB
- g838099ex99_2p28g1.jpg (GRAPHIC) — 621KB
- g838099ex99_2p29g1.jpg (GRAPHIC) — 362KB
- g838099ex99_2p2g1.jpg (GRAPHIC) — 619KB
- g838099ex99_2p30g1.jpg (GRAPHIC) — 102KB
- g838099ex99_2p31g1.jpg (GRAPHIC) — 292KB
- g838099ex99_2p32g1.jpg (GRAPHIC) — 300KB
- g838099ex99_2p33g1.jpg (GRAPHIC) — 191KB
- g838099ex99_2p34g1.jpg (GRAPHIC) — 352KB
- g838099ex99_2p35g1.jpg (GRAPHIC) — 335KB
- g838099ex99_2p3g1.jpg (GRAPHIC) — 347KB
- g838099ex99_2p4g1.jpg (GRAPHIC) — 334KB
- g838099ex99_2p5g1.jpg (GRAPHIC) — 469KB
- g838099ex99_2p6g1.jpg (GRAPHIC) — 372KB
- g838099ex99_2p7g1.jpg (GRAPHIC) — 390KB
- g838099ex99_2p8g1.jpg (GRAPHIC) — 320KB
- g838099ex99_2p9g1.jpg (GRAPHIC) — 321KB
- g838099g0604124055100.jpg (GRAPHIC) — 3KB
- 0001193125-24-153625.txt ( ) — 16403KB
- annx-20240604.xsd (EX-101.SCH) — 3KB
- annx-20240604_lab.xml (EX-101.LAB) — 18KB
- annx-20240604_pre.xml (EX-101.PRE) — 11KB
- d838099d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated June 4, 2024, titled "Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome." 99.2 Annexon, Inc. Presentation dated June 2024 104.1 Cover Page Interactive Data File, formatted in inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 4, 2024 Annexon, Inc. By: /s/ Jennifer Lew Jennifer Lew Executive Vice President and Chief Financial Officer